| Baseline values . | β (95% CI) . | P-value . |
|---|---|---|
| Age, years | 0.002 (0.00; 0.004) | .1 |
| Male sex | –0.2 (–0.2; –0.1) | <.001 |
| BMI, kg/m2 | –0.002 (–0.007; 0.002) | .3 |
| PKD1 genotype | 0.01 (–0.03; 0.06) | .6 |
| eGFR, mL/min/1.73 m2 | 0.002 (0.001; 0.004) | <.001 |
| htTKV, mL/m | 0.05 (–0.04; 0.13) | .3 |
| Tolvaptan treatment | 0.02 (–0.05; 0.08) | .6 |
| Diuretic treatment | –0.04 (–0.09; 0.01) | .2 |
| 25-OH vitamin D, nmol/mL | –0.01 (–0.1–0.08) | .8 |
| PTH, pmol/mL | –0.2 (–0.3; –0.06) | .002 |
| Serum calcium, mmol/dL | 0.4 (–0.8; 1.5) | .6 |
| Plasma copeptin, pmol/L | –0.08 (–0.1; –0.08) | .03 |
| FGF-23, RU/mL | 0.1 (0.03; 0.2) | .01 |
| Proteinuria (g/24 h) | 0.01 (–0.08; 0.08) | 1.0 |
| Urea excretion (mmol/24 h) | –0.00 (–0.00; 0.000) | .3 |
| Baseline values . | β (95% CI) . | P-value . |
|---|---|---|
| Age, years | 0.002 (0.00; 0.004) | .1 |
| Male sex | –0.2 (–0.2; –0.1) | <.001 |
| BMI, kg/m2 | –0.002 (–0.007; 0.002) | .3 |
| PKD1 genotype | 0.01 (–0.03; 0.06) | .6 |
| eGFR, mL/min/1.73 m2 | 0.002 (0.001; 0.004) | <.001 |
| htTKV, mL/m | 0.05 (–0.04; 0.13) | .3 |
| Tolvaptan treatment | 0.02 (–0.05; 0.08) | .6 |
| Diuretic treatment | –0.04 (–0.09; 0.01) | .2 |
| 25-OH vitamin D, nmol/mL | –0.01 (–0.1–0.08) | .8 |
| PTH, pmol/mL | –0.2 (–0.3; –0.06) | .002 |
| Serum calcium, mmol/dL | 0.4 (–0.8; 1.5) | .6 |
| Plasma copeptin, pmol/L | –0.08 (–0.1; –0.08) | .03 |
| FGF-23, RU/mL | 0.1 (0.03; 0.2) | .01 |
| Proteinuria (g/24 h) | 0.01 (–0.08; 0.08) | 1.0 |
| Urea excretion (mmol/24 h) | –0.00 (–0.00; 0.000) | .3 |
Log transformation performed in non-normally distributed variables: htTKV, 25-OH vitamin D, PTH, serum calcium, plasma copeptin, FGF-23 and proteinuria.
Bold values means significant difference with p < 0.05.
| Baseline values . | β (95% CI) . | P-value . |
|---|---|---|
| Age, years | 0.002 (0.00; 0.004) | .1 |
| Male sex | –0.2 (–0.2; –0.1) | <.001 |
| BMI, kg/m2 | –0.002 (–0.007; 0.002) | .3 |
| PKD1 genotype | 0.01 (–0.03; 0.06) | .6 |
| eGFR, mL/min/1.73 m2 | 0.002 (0.001; 0.004) | <.001 |
| htTKV, mL/m | 0.05 (–0.04; 0.13) | .3 |
| Tolvaptan treatment | 0.02 (–0.05; 0.08) | .6 |
| Diuretic treatment | –0.04 (–0.09; 0.01) | .2 |
| 25-OH vitamin D, nmol/mL | –0.01 (–0.1–0.08) | .8 |
| PTH, pmol/mL | –0.2 (–0.3; –0.06) | .002 |
| Serum calcium, mmol/dL | 0.4 (–0.8; 1.5) | .6 |
| Plasma copeptin, pmol/L | –0.08 (–0.1; –0.08) | .03 |
| FGF-23, RU/mL | 0.1 (0.03; 0.2) | .01 |
| Proteinuria (g/24 h) | 0.01 (–0.08; 0.08) | 1.0 |
| Urea excretion (mmol/24 h) | –0.00 (–0.00; 0.000) | .3 |
| Baseline values . | β (95% CI) . | P-value . |
|---|---|---|
| Age, years | 0.002 (0.00; 0.004) | .1 |
| Male sex | –0.2 (–0.2; –0.1) | <.001 |
| BMI, kg/m2 | –0.002 (–0.007; 0.002) | .3 |
| PKD1 genotype | 0.01 (–0.03; 0.06) | .6 |
| eGFR, mL/min/1.73 m2 | 0.002 (0.001; 0.004) | <.001 |
| htTKV, mL/m | 0.05 (–0.04; 0.13) | .3 |
| Tolvaptan treatment | 0.02 (–0.05; 0.08) | .6 |
| Diuretic treatment | –0.04 (–0.09; 0.01) | .2 |
| 25-OH vitamin D, nmol/mL | –0.01 (–0.1–0.08) | .8 |
| PTH, pmol/mL | –0.2 (–0.3; –0.06) | .002 |
| Serum calcium, mmol/dL | 0.4 (–0.8; 1.5) | .6 |
| Plasma copeptin, pmol/L | –0.08 (–0.1; –0.08) | .03 |
| FGF-23, RU/mL | 0.1 (0.03; 0.2) | .01 |
| Proteinuria (g/24 h) | 0.01 (–0.08; 0.08) | 1.0 |
| Urea excretion (mmol/24 h) | –0.00 (–0.00; 0.000) | .3 |
Log transformation performed in non-normally distributed variables: htTKV, 25-OH vitamin D, PTH, serum calcium, plasma copeptin, FGF-23 and proteinuria.
Bold values means significant difference with p < 0.05.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
